UY31096A1 - PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATIN AGENT AND AN HMG-COA REDUCTASA INHIBITING AGENT - Google Patents

PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATIN AGENT AND AN HMG-COA REDUCTASA INHIBITING AGENT

Info

Publication number
UY31096A1
UY31096A1 UY31096A UY31096A UY31096A1 UY 31096 A1 UY31096 A1 UY 31096A1 UY 31096 A UY31096 A UY 31096A UY 31096 A UY31096 A UY 31096A UY 31096 A1 UY31096 A1 UY 31096A1
Authority
UY
Uruguay
Prior art keywords
agent
lipstatin
pharmaceutical compositions
hmg
combination
Prior art date
Application number
UY31096A
Other languages
Spanish (es)
Inventor
Victor Guillermo Alvarez Ochoa
Josefina Santos Murillo
Maria Elena Garcia Armenta
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of UY31096A1 publication Critical patent/UY31096A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

La presente invencion esta relacionada con diversas composiciones farmacéuticas que están compuestas por la combinacion sinérgica de un agente derivado hidrogenado de lipstatina, tal como lo es el principio activo: Orlistat y un agente inhibidor de la enzima HMG-CoA reductasa, tal como lo son los principios activos: Simvastatina y/o Rosuvastatina, además de excipientes farmacéuticamente aceptables, mismas que se encuentran formuladas en una sola unidad de dosificacion para ser administradas por vía oral y están indicadas para la prevencion y/o tratamiento de la hipercolesterolemia, trigliceridemia, el sobrepeso y la obesidad.The present invention is related to various pharmaceutical compositions that are composed of the synergistic combination of a hydrogenated derivative agent of lipstatin, such as the active ingredient: Orlistat and an inhibitor of the enzyme HMG-CoA reductase, such as active ingredients: Simvastatin and / or Rosuvastatin, in addition to pharmaceutically acceptable excipients, which are formulated in a single dosage unit to be administered orally and are indicated for the prevention and / or treatment of hypercholesterolemia, triglyceridemia, overweight and obesity.

UY31096A 2007-05-21 2008-05-19 PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATIN AGENT AND AN HMG-COA REDUCTASA INHIBITING AGENT UY31096A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2007006092A MX2007006092A (en) 2007-05-21 2007-05-21 Pharmaceutical compositions combining a hydrogenated lipstatin derived agent and a hmg-coa reductase inhibiting agent.

Publications (1)

Publication Number Publication Date
UY31096A1 true UY31096A1 (en) 2008-11-28

Family

ID=40032121

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31096A UY31096A1 (en) 2007-05-21 2008-05-19 PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATIN AGENT AND AN HMG-COA REDUCTASA INHIBITING AGENT

Country Status (4)

Country Link
AR (1) AR066667A1 (en)
MX (1) MX2007006092A (en)
UY (1) UY31096A1 (en)
WO (1) WO2008143491A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357812A (en) * 2019-08-03 2019-10-22 黄泳华 The eutectic compound being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor
CN110314232A (en) * 2019-08-03 2019-10-11 黄泳华 The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319170B2 (en) * 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives

Also Published As

Publication number Publication date
WO2008143491A1 (en) 2008-11-27
AR066667A1 (en) 2009-09-02
MX2007006092A (en) 2009-02-25

Similar Documents

Publication Publication Date Title
ECSP066990A (en) FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
CO6251259A2 (en) PHARMACEUTICAL FORMULATIONS OF ESTRIOL IN LOW DOSE
ATE553750T1 (en) SOLID ORAL MICROPARTICLE PHARMACEUTICAL FORM FOR PROTECTION AGAINST ABUSE
WO2009026473A3 (en) Stabilized therapeutic compositions and formulations
PE20150773A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PHENYLEPHRINE
AR077138A1 (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT HCV
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
UY30847A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
PE20130147A1 (en) PHARMACEUTICAL COMBINATION OF THEOBROMINE AND A NON-OPIOID ANTITUSSIVE AGENT
AR052048A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CELLULITE
UY31096A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF A HYDROGEN DERIVATIVE LIPSTATIN AGENT AND AN HMG-COA REDUCTASA INHIBITING AGENT
AR066666A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT
CO6270220A2 (en) PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE COMBINATION OF A NON-STEROID ANTIINFLAMOTORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP DROPPED ARTHRITIS AND RELATED DISEASES
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
ECSP12012352A (en) SUSTAINED RELEASE THERAPEUTIC AGENT FOR HYPERTENSION AND RENAL DYSFUNCTION
ECSP099801A (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN INHIBITING AGENT OF THE HMG-CoA REDUCTASE ENZYME AND AN INHIBITING AGENT OF THE GASTROINTESTINAL LIPASE ENZYME
CO6241114A2 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF THE CIPROFLOXACINE ANTIMICROBIAL AGENT AND THE ASCORBIC ACID ANTIOXIDANT AGENT FOR THE TREATMENT OF URINARY INFECTION
CO6140029A2 (en) SYNERGIC FRAMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN ALFA-REDUCTASE 5 ENZYME INHIBITOR AND AN ALFA-ADRENERGIC RECEIVER 1 ANTAGONIST
ECSP12012332A (en) ASSOCIATION OF INHIBITORS OF XANTINA OXIDASE AND THE INSTATINE AND ITS USE
AR084435A1 (en) COMBINATION AND COMPOSITION FOR OBESITY TREATMENT
MX2010009961A (en) Enhanced transmucosal composition and dosage form.
UY31157A1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN INHIBITING AGENT OF THE HMG-COA REDUCTASE ENZYME AND AN INHIBITING AGENT OF THE GASTRONTESTINAL ENZYME LIPASA
AR067700A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTIMICROBIAL AGENT AND A SELECTIVE INHIBITING AGENT OF THE ENCEPHALINE ENZYME INDICATED FOR THE CONTOL AND TREATMENT OF THE ACUTE BACTERIAL DIARRHEA
PE20091836A1 (en) FORMULATIONS FOR THE EAR TO TREAT OTIC DISEASES AND CONDITIONS

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20140924